Tarsus Pharmaceuticals, Inc.
NASDAQTarsus Pharmaceuticals is having its best week in months, with the stock up 12% to $70.55 — and the more interesting question is whether the options market's retreat from caution reflects genuine conviction or simply the removal of hedges that have now expired. The options story has shifted materially since last week's note. The put/call ratio has climbed back to 1.24 from the…
Snapshot as of 6 Aug 2026
Tarsus Pharmaceuticals is having its best week in months, with the stock up 12% to $70.55 — and the more interesting question is whether the options market's retreat from caution reflects genuine conviction or simply…
Tarsus Pharmaceuticals enters July with a notable divergence: options traders have swung sharply toward calls just as short sellers trim positions modestly — a combination that places the stock in an unusually…
Tarsus Pharmaceuticals just handed bears a difficult week, reporting Q1 results that cleared consensus by a wide margin — and doing so into a short interest position that has already been steadily unwinding. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TARS — free to start on ORTEX.
Sign up for free →Open TARS on ORTEX